内部人士可能会获得普通股东无法获得的可观财务利益。
拟议的交易可能包含限制更优竞争报价的条款。
鼓励股东与本公司联系，讨论他们的权利和选择，且无需支付任何费用或承担任何义务。我们将以风险代理的方式处理任何事务，您无需承担我们的法律费用或开支。
, /PRNewswire/ -- Halper Sadeh LLC，一家投资者权益法律事务所，正在调查以下公司是否可能违反联邦证券法和/或对股东的信托责任：
Select Medical Holdings Corporation (NYSE: SEM) 以每股 16.50 美元的现金出售给由 Select Medical 高管和董事领导的财团。如果您是 Select Medical 的股东， 请点击这里了解您的权利和选择 。
XOMA Royalty Corporation (NASDAQ: XOMA) 以每股 39.00 美元的价格出售给 Ligand Pharmaceuticals Incorporated。如果您是 XOMA 的股东， 请点击这里了解您的权利和选择 。
Soleno Therapeutics, Inc. (NASDAQ: SLNO) 以每股 53.00 美元的现金出售给 Neurocrine Biosciences。如果您是 Soleno 的股东， 请点击这里了解您的法律权利和选择。
KORE Group Holdings, Inc. (NYSE: KORE) 以每股 9.25 美元的价格出售给 Searchlight Capital Partners, L.P.和 Abry Partners。如果您是 KORE 的股东， 请点击这里了解您的权利和选择 。
代表股东，Halper Sadeh LLC 可能寻求增加对价、额外披露和信息，或其他救济和利益。
Halper Sadeh LLC 代表全球受证券欺诈和公司不当行为影响的投资者。我们的律师在实施公司改革和为受欺诈投资者追回数百万美元方面发挥了重要作用。
律师广告。以往的结果并不保证类似的结果。
联系信息：
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
世界贸易中心一号
85 层
纽约，NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
来源 Halper Sadeh LLP
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA4Jk5ld3NJdGVtSWQ9Tlk1NTM1MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDgxNzU3UFJfTkVXU19VU1BSX19fX19OWTU1MzUz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA4Jk5ld3NJdGVtSWQ9Tlk1NTM1MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDgxNzU3UFJfTkVXU19VU1BSX19fX19OWTU1MzUz"/>

Soleno治疗

KORE

Select医药控股

标记临床研究

Halper Sadeh LLC 正在调查 Select Medical Holdings Corporation、XOMA Royalty Corporation、Soleno Therapeutics 和 KORE Group Holdings 是否存在潜在的联邦证券法违规和违反信托责任的行为。该公司担心内部人士可能会在普通股东的利益受损的情况下获得财务利益。鼓励股东联系该公司，讨论他们在这些公司拟议出售方面的权利和选择。Halper Sadeh LLC 旨在为股东争取更高的对价和其他利益

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
<div class="lb-trans">内部人士可能会获得普通股东无法获得的可观财务利益。
</div>The proposed transactions may contain terms that could limit superior competing offers.
<div class="lb-trans">拟议的交易可能包含限制更优竞争报价的条款。
</div>Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
<div class="lb-trans">鼓励股东与本公司联系，讨论他们的权利和选择，且无需支付任何费用或承担任何义务。我们将以风险代理的方式处理任何事务，您无需承担我们的法律费用或开支。
</div>, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
<div class="lb-trans">, /PRNewswire/ -- Halper Sadeh LLC，一家投资者权益法律事务所，正在调查以下公司是否可能违反联邦证券法和/或对股东的信托责任：
</div>Select Medical Holdings Corporation (NYSE: SEM)'s sale to a consortium led by Select Medical executives and directors for $16.50 in cash per share. If you are a Select Medical shareholder, click here to learn more about your rights and options .
<div class="lb-trans">Select Medical Holdings Corporation (NYSE: SEM) 以每股 16.50 美元的现金出售给由 Select Medical 高管和董事领导的财团。如果您是 Select Medical 的股东， 请点击这里了解您的权利和选择 。
</div>XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share. If you are a XOMA shareholder, click here to learn more about your rights and options .
<div class="lb-trans">XOMA Royalty Corporation (NASDAQ: XOMA) 以每股 39.00 美元的价格出售给 Ligand Pharmaceuticals Incorporated。如果您是 XOMA 的股东， 请点击这里了解您的权利和选择 。
</div>Soleno Therapeutics, Inc. (NASDAQ: SLNO)'s sale to Neurocrine Biosciences for $53.00 per share in cash. If you are a Soleno shareholder, click here to learn more about your legal rights and options.
<div class="lb-trans">Soleno Therapeutics, Inc. (NASDAQ: SLNO) 以每股 53.00 美元的现金出售给 Neurocrine Biosciences。如果您是 Soleno 的股东， 请点击这里了解您的法律权利和选择。
</div>KORE Group Holdings, Inc. (NYSE: KORE)'s sale to Searchlight Capital Partners, L.P. and Abry Partners for $9.25 per share. If you are a KORE shareholder, click here to learn more about your rights and options .
<div class="lb-trans">KORE Group Holdings, Inc. (NYSE: KORE) 以每股 9.25 美元的价格出售给 Searchlight Capital Partners, L.P.和 Abry Partners。如果您是 KORE 的股东， 请点击这里了解您的权利和选择 。
</div>On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
<div class="lb-trans">代表股东，Halper Sadeh LLC 可能寻求增加对价、额外披露和信息，或其他救济和利益。
</div>Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
<div class="lb-trans">Halper Sadeh LLC 代表全球受证券欺诈和公司不当行为影响的投资者。我们的律师在实施公司改革和为受欺诈投资者追回数百万美元方面发挥了重要作用。
</div>Attorney Advertising. Prior results do not guarantee a similar outcome.
<div class="lb-trans">律师广告。以往的结果并不保证类似的结果。
</div>Contact Information:
<div class="lb-trans">联系信息：
</div>Halper Sadeh LLC
<div class="lb-trans">Halper Sadeh LLC
</div>Daniel Sadeh, Esq.
<div class="lb-trans">Daniel Sadeh, Esq.
</div>Zachary Halper, Esq.
<div class="lb-trans">Zachary Halper, Esq.
</div>One World Trade Center
<div class="lb-trans">世界贸易中心一号
</div>85th Floor
<div class="lb-trans">85 层
</div>New York, NY 10007
<div class="lb-trans">纽约，NY 10007
</div>(212) 763-0060
<div class="lb-trans">(212) 763-0060
</div>[email protected]
<div class="lb-trans">[email protected]
</div>[email protected]
<div class="lb-trans">[email protected]
</div>https://www.halpersadeh.com
<div class="lb-trans">https://www.halpersadeh.com
</div>SOURCE Halper Sadeh LLP
<div class="lb-trans">来源 Halper Sadeh LLP
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA4Jk5ld3NJdGVtSWQ9Tlk1NTM1MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDgxNzU3UFJfTkVXU19VU1BSX19fX19OWTU1MzUz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY55353&amp;Transmission_Id=202605081757PR_NEWS_USPR_____NY55353&amp;DateId=20260508"/>

Select 医药控股、XOMA Royalty、Soleno 治疗、KORE 是否为其股东争取到了公平的交易？